China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.
CR Sanjiu, a subsidiary of China Resources Pharmaceutical Group Ltd., reported a notable financial performance for the year ended December 31, 2024. The company achieved an 11.63% increase in revenue and an 18.05% rise in net profit attributable to shareholders. The board has proposed a cash dividend distribution, reflecting strong shareholder returns and a positive outlook for the company’s financial health.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, primarily focusing on medical and pharmaceutical products. It holds a significant market position with its subsidiary CR Sanjiu, which is listed on the Shenzhen Stock Exchange.
YTD Price Performance: -11.76%
Average Trading Volume: 1,702
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €3.92B
See more data about 3320 stock on TipRanks’ Stock Analysis page.